Vascular Pharmacology : Impact Factor & More
eISSN: 1879-3649pISSN: 1537-1891
Share this on:
Key Metrics
CiteScore 
10.3
Impact Factor
< 5
SJR
Q1Physiology
SNIP
1.47
Recommended pre-submission checks
Powered by 
Run standard language and technical checks to improve your manuscript – before you submit
Technical Compliance
Ensure manuscript complies with standard submission guidelines.
Language Quality
Improve clarity, grammar, and academic writing style.
A comprehensive report covering all these checks awaits you.
Topics Covered on Vascular Pharmacology
Vascular Pharmacology Journal Specifications
| Overview | |
| Publisher | ELSEVIER SCIENCE INC |
| Language | English |
| Frequency | Monthly |
| General Details | |
| Language | English |
| Frequency | Monthly |
| Publication Start Year | 2002 |
| Publisher URL | Visit website |
| Website URL | Visit website |
View less
Planning to publish in Vascular Pharmacology ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Recently Published Papers in Vascular Pharmacology
Characterization of an adjustable partial portal vein ligation model reveals flow-dependent intimal and medial remodeling of the extrahepatic portal vein.
- 1 Dec 2026
- Vascular pharmacology
Integrative genetic analyses for drug repurposing identify emodin as a candidate modulator of STAT3 signaling in abdominal aortic aneurysm.
- 1 Dec 2026
- Vascular pharmacology
Aquaporin-1 facilitates the transport of hydrogen peroxide and nitric oxide during endothelium-dependent vasorelaxation.
- 1 Dec 2026
- Vascular pharmacology
CRISPR-based genome editing of smooth muscle cells: Disease models, therapeutic applications, and future perspectives.
- 1 Dec 2026
- Vascular pharmacology
Beyond catecholamine escalation: Receptor desensitization and endogenous vasopressor failure, and extracorporeal circuit biocompatibility after cardiopulmonary bypass—A narrative review
- 1 Dec 2026
- Vascular Pharmacology
Pan-peroxisome proliferator-activated receptor agonist IVA337 alleviates secondary lymphedema via inhibiting TGFβ/SMAD2/3 signaling pathway.
- 1 Dec 2026
- Vascular pharmacology
Characterization of an adjustable partial portal vein ligation model reveals flow-dependent intimal and medial remodeling of the extrahepatic portal vein.
- 1 Dec 2026
- Vascular pharmacology
Integrative genetic analyses for drug repurposing identify emodin as a candidate modulator of STAT3 signaling in abdominal aortic aneurysm.
- 1 Dec 2026
- Vascular pharmacology
Aquaporin-1 facilitates the transport of hydrogen peroxide and nitric oxide during endothelium-dependent vasorelaxation.
- 1 Dec 2026
- Vascular pharmacology
CRISPR-based genome editing of smooth muscle cells: Disease models, therapeutic applications, and future perspectives.
- 1 Dec 2026
- Vascular pharmacology
Beyond catecholamine escalation: Receptor desensitization and endogenous vasopressor failure, and extracorporeal circuit biocompatibility after cardiopulmonary bypass—A narrative review
- 1 Dec 2026
- Vascular Pharmacology
Pan-peroxisome proliferator-activated receptor agonist IVA337 alleviates secondary lymphedema via inhibiting TGFβ/SMAD2/3 signaling pathway.
- 1 Dec 2026
- Vascular pharmacology
FAQs on Vascular Pharmacology
How long has Vascular Pharmacology been actively publishing? 
What is the publishing frequency of Vascular Pharmacology?
How many articles did Vascular Pharmacology publish last year?
What is the eISSN & pISSN for Vascular Pharmacology?
What is Citescore for Vascular Pharmacology?
What is SNIP score for Vascular Pharmacology?
What is the SJR for Vascular Pharmacology?
Who is the publisher of Vascular Pharmacology?
